Myoseverin
Based on 1 Customer Validation
Myoseverin is a microtubule-binding molecule and angiogenesis inhibitor. Myoseverin can induce the reversible fission of multinucleated myotubes into mononucleated fragments. In addition, Myoseverin exerts anti-angiogenic effects by inhibiting endothelial cell function and endothelial progenitor cell differentiation.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.17%
- No. CAS: 267402-71-1
- Fòrmula: C24H28N6O2
- Peso molecular:432.52
-
Almacenamiento:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
Anti-Aging Compound Library
HY-L034
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Cytoskeleton Compound Library
HY-L060
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Obesity Compound Library
HY-L087
-
Heterocyclic Compound Library
HY-L138
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Ver todos los productos específicos de isoformas DNA/RNA Synthesis
More
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>10 μM
Compound: Myoseverin
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 31610375] |
| CCRF-CEM | IC50 |
5.7 μM
Compound: myoseverin
|
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
|
[PMID: 19349183] |
| HCT-116 | IC50 |
3.3 μM
Compound: myoseverin
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 19349183] |
| HCT-116 | IC50 |
7.82 μM
Compound: Myoseverin
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 31610375] |
| HepG2 | IC50 |
3.06 μM
Compound: Myoseverin
|
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 31610375] |
| MCF7 | IC50 |
11.5 μM
Compound: myoseverin
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 19349183] |
| MES-SA | IC50 |
8.5 μM
Compound: myoseverin
|
Cytotoxicity against human MES-SA cells after 72 hrs by MTT assay
Cytotoxicity against human MES-SA cells after 72 hrs by MTT assay
|
[PMID: 19349183] |
| SW48 | IC50 |
2.7 μM
Compound: myoseverin
|
Cytotoxicity against human SW48 cells after 72 hrs by MTT assay
Cytotoxicity against human SW48 cells after 72 hrs by MTT assay
|
[PMID: 19349183] |
| SW480 | IC50 |
4.8 μM
Compound: myoseverin
|
Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
|
[PMID: 19349183] |
| U-937 | GI50 |
4 μM
Compound: Myoseverin
|
Growth inhibition of human U937 cells
Growth inhibition of human U937 cells
|
[PMID: 11741468] |
Myoseverin (20 μM; 24 h) promotes the fission of multinucleated myotubes into mononucleated fragments with "bead-on-a-string" constriction morphology, and causes disassembly of the microtubule cytoskeleton with microtubules aggregating around the nucleus and fragmenting in mouse C2C12 myotubes[1].
Myoseverin (20 μM; 24 h) promotes DNA synthesis and colony formation, and regulates the expression of more than 93 genes, involving extracellular matrix remodeling, growth factors, immunomodulatory pathways, etc in mouse C2C12 myotubes[1].
Myoseverin (0-80 μM; 1-7 d) inhibits cell proliferation (IC50: 8 μM) in a reversible manner and suppresses cell migration in human umbilical vein endothelial cells[2].
Myoseverin (0-80 μM; 7 d) reduces the differentiation of endothelial progenitor cells into adherent cells in human cord blood mononuclear cells[2].
Myoseverin (0-20 μM; 7 d) inhibits the acetylated low-density lipoprotein (ac-LDL) uptake ability and the expression of endothelial markers (KDR, CD31, vWF) in endothelial progenitor cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human umbilical vein endothelial cells
-
Concentration:0, 2.5, 5, 10, 20, 40 and 80 μM
-
Incubation Time:72 h
-
Result:Inhibited the cell viability.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:4.5-day-old chick embryos (chorioallantoic membrane (CAM) model was established by normal incubation of eggs)[2]
-
Dosage:0, 0.1, 1, 5 and 10 μg/embryo
-
Administration:Topical application; single dose (48 h)
-
Result:Did not show significant inhibition at low doses (0.1 μg or 1 μg/embryo).
Potently inhibited in vivo angiogenesis by showing a marked inhibition zone around the implanted cover slip without affecting embryo’s viability at 5 μg or 10 μg/embryo.
Chemical Information
-
No. CAS 267402-71-1
-
Appearance Solid
-
Peso molecular 432.52
-
Fòrmula C24H28N6O2
-
Color Off-white to light yellow
-
SMILES
CC(N1C=NC2=C(NCC3=CC=C(OC)C=C3)N=C(NCC4=CC=C(OC)C=C4)N=C12)C
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
DMSO : 250 mg/mL (578.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (4.81 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (4.81 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Rosania GR, et al. Myoseverin, a microtubule-binding molecule with novel cellular effects. Nat Biotechnol. 2000;18(3):304-308. [Content Brief]
[2]. Park HE, et al. Myoseverin is a potential angiogenesis inhibitor by inhibiting endothelial cell function and endothelial progenitor cell differentiation. DNA Cell Biol. 2006 Sep;25(9):514-22. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3120 mL | 11.5602 mL | 23.1203 mL | 57.8008 mL |
| 5 mM | 0.4624 mL | 2.3120 mL | 4.6241 mL | 11.5602 mL | |
| 10 mM | 0.2312 mL | 1.1560 mL | 2.3120 mL | 5.7801 mL | |
| 15 mM | 0.1541 mL | 0.7707 mL | 1.5414 mL | 3.8534 mL | |
| 20 mM | 0.1156 mL | 0.5780 mL | 1.1560 mL | 2.8900 mL | |
| 25 mM | 0.0925 mL | 0.4624 mL | 0.9248 mL | 2.3120 mL | |
| 30 mM | 0.0771 mL | 0.3853 mL | 0.7707 mL | 1.9267 mL | |
| 40 mM | 0.0578 mL | 0.2890 mL | 0.5780 mL | 1.4450 mL | |
| 50 mM | 0.0462 mL | 0.2312 mL | 0.4624 mL | 1.1560 mL | |
| 60 mM | 0.0385 mL | 0.1927 mL | 0.3853 mL | 0.9633 mL | |
| 80 mM | 0.0289 mL | 0.1445 mL | 0.2890 mL | 0.7225 mL | |
| 100 mM | 0.0231 mL | 0.1156 mL | 0.2312 mL | 0.5780 mL |
Myoseverin Related Classifications
HY-W008956 Related Classifications
Powered by Bioz